EMA starts safety-related review of obesity drug
![Photo: Rob Acket/EMA](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article12767010.ece/ALTERNATES/schema-16_9/doc7ejgsqno3d01marnabmd.jpg)
Following a request from the Romanian medicines agency, the European Medicines Agency (EMA) has started reviewing the substance amfepramone, which is an ingredient in several drugs used for treating obesity.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
EMA clarifies: No Russian application for vaccine approval
For subscribers